Tools for Practice Outils pour la pratique

#151 Rotavirus Vaccine: A shot to get off the pot(ty)

What are the benefits and risks of the rotavirus vaccine?

In developed countries, rotavirus vaccine prevents serious diarrhea for one in 22 and reduces hospitalizations for one in 100. There does not appear to be an increase in intussusception rates. 

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

  • For monovalent and pentavalent rotavirus vaccine (RV1 and RV5, respectively)   
    • Systematic Review (RV1: 29 Randomized Controlled Trials (RCTs), 101,671 infants; RV5: 12 RCTs, 84,592 infants), vaccine versus placebo in developed (western) countries.1 Statistically significant results at two years:  
      • Any rotavirus diarrhea: 
        • RV1: Relative Risk (RR) 0.33 (95% confidence interval, 0.21-0.50). 
        • RV5: RR 0.36 (95% confidence interval 0.25-0.50). 
          • Placebo rate ~9%, vaccine rate ~3%.  
          • Number Needed tTreat (NNT) ~17, either vaccine. 
      • Severe rotavirus diarrhea, NNT ~50, either vaccine. 
      • RV1 (no or too little data from RV5): 
        • Any diarrhea, NNT ~40. 
        • Any severe diarrhea, NNT ~22. 
        • Hospitalizations, NNT ~100. 
      • Mortality: Ndifference. 
      • Limitations: Inconsistent definition of ‘severe diarrhea’ in trials (varies from rotavirus diarrhea scales to hospitalization requiring rehydration therapy).   
    • Safety:  
      • Reactions to immunization similar between vaccine and placebo: rates were fever (38-41%), diarrhea (7-25%), vomiting (13-17%).1,2 
      • No increase in intussusception in RCTs or subsequent surveillance/observational data.1-5 
  • Rotavirus transmission is fecal-oral and fomites (including toys) with a 1-5 day incubation.6 
  • An estimated 80% of children have rotavirus gastroenteritis by age five.7  
    • One in 62-312 children are hospitalized for rotavirus.6 
    • Most (90%) Canadian cases occur December-April and 63% affect children <2 years old.8,9 
  • Licenced oral vaccines include: 
    • RV1 (Rotarix®; GlaxoSmithKline): Live attenuated, human monovalent rotavirustwo oral doses (two and four months). 
    • RV5 (RotaTeq®; Merck): Live human-bovine reassortmentpentavalent rotavirus, three oral doses (two, four, and six months). 
  • Publicly funded in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec, Prince Edward Island, Northwest Territoriesand Yukon. 
  • Approximately $165-$200 per vaccine series. 

Latest Tools for Practice
Derniers outils pour la pratique

#367 Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

What are the risks and benefits of ubrogepant for the acute treatment of episodic migraines?
Read Lire 0.25 credits available Crédits disponibles

#366 Looking for Closure: Managing simple excisions or wounds efficiently

What are some options for efficiency in wound closure?
Read Lire 0.25 credits available Crédits disponibles

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session

  • Clark Svrcek MD
  • G. Michael Allan MD CCFP

1. Soares-Weiser K, MacLehose H, Ben-Aharon I, et al. Cochrane Database Syst Rev. 2012; (11):CD008521.

2. Vesikari T, Matson DO, Dennehy P, et al. NEJM. 2006; 354(1):23-33.

3. Dennehy PH, Brady RC, Halperin SA, et al. Pediatr Infect Dis J. 2005; 24(6):481-8.

4. Dennehy PH. 2006. Vaccine. 2006; 24(18):3780-1.

5. CDC. MMWR. 2007; 56(10):218-22. Last accessed July 25, 2015.

6. Salvadori M, Le Saux N. Paediatric & Child Health. 2010; 15(8):519-23. Reaffirmed Feb. 28, 2015. Last accessed July 27, 2015.

7. Cortese MM, Parashar UD. MMWR Recommendations and Reports. 2009; 58(RR02):1-25. Last accessed July 25, 2015.

8. Ford-Jones EL, Wang E, Petric M, et al. Arch Pediatr Adolesc Med. 2000; 154:586-93.

9. Le Saux N, Bettinger JA, Halperin SA, et al. Pediatr Infect Dis J. 2010; 29(9):879-82.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.